Pfizer Inc. is doubling down on the booming weight-loss drug race, with CEO Albert Bourla declaring the company will be a "formidable competitor" after securing a $10 billion deal to acquire ...

Pfizer (PFE) CEO and chairman Albert Bourla told Yahoo Finance Executive Editor Brian Sozzi during Yahoo Finance's annual Investconference that the $10 billion acquisition of GLP-1 maker Metsera (MTSR ...

Find insight on GSK’s acquisition of RAPT Therapeutics, Novartis and more in the latest Market Talks covering Health Care.

In 2025's third quarter, multiple large vaccine developers, including Pfizer and GSK, saw vaccine sales tick up globally ...

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare ...

Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the industry and won't let go anytime soon. Even so, Lilly could carve out a niche ...

Pfizer’s battle with Novo Nordisk over control of obesity drug developer Metsera is getting nasty. After Pfizer apparently sealed a $4.9 billion purchase of Metsera in September, Novo Nordisk swooped ...

Amid Novo Nordisk and Pfizer’s whiplash contest for obesity biotech Metsera, Novo’s CEO has, quite literally, told his company's rival to put its money where its mouth is. “Novo Nordisk and Pfizer ...

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...